<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01596530</url>
  </required_header>
  <id_info>
    <org_study_id>D0102C00019</org_study_id>
    <nct_id>NCT01596530</nct_id>
  </id_info>
  <brief_title>Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment</brief_title>
  <acronym>CHIVE</acronym>
  <official_title>A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study to Assess the Biological Activity of AZD8931 in Patients With Early Breast Cancer Who Are Ineligible for Treatment With Trastuzumab as Defined by IHC Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      To compare the activity of AZD8931 against placebo on the cell markers in cancer tumours
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study to Assess the
      Biological Activity of AZD8931 in Patients with Early Breast Cancer who are Ineligible for
      Treatment with trastuzumab as defined by IHC status
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    All AstraZeneca sponsored clinical trials of AZD8931 have been halted
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the effects of AZD8931 versus placebo on cytoplasmic p-MAPK after 7 days or more days of treatment</measure>
    <time_frame>Day 7 - Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the effects of AZD8931 versus placebo on p-EGFR, p-erbB2, p-erbB3 NUCLEAR p-Mapk, p-AKT and Ki67 after 7 or more days of treatment</measure>
    <time_frame>Day 7 - Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment sof the safety and tolerability of AZD8931 as assessed by incidence of adverse events during the course of the study.</measure>
    <time_frame>From study entry through to 30 days post treatment (Day 44 maximum)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the plasma PK of AZD8931</measure>
    <time_frame>Day 1 - Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the effects of AZD8931 versus placebo on other biomarkers including but not limited to, erbB ligands, pER, PTEN, erbB receptor homo- and hetero- dimers, total MAPK, apoptosis markers and total AKT after 7 or more days of treatment.</measure>
    <time_frame>Day 7 - Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establishing the baseline tumour characteristics, including but not limited to ER, PR and HER-2 status</measure>
    <time_frame>Day -28 to Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploration of the relationship between AZD8931 exposure (PK in plasma and tumour) and a selection of secondary biomarkers (e.g. p-EGFR, nuclear p-MAPK, Ki67 and apoptosis markers after ?7 days of treatment), if possible.</measure>
    <time_frame>Day 1 - Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory, vitals signs and ECG data</measure>
    <time_frame>Day 1 - Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Breast Neoplasm</condition>
  <arm_group>
    <arm_group_label>AZD8931</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AZD8931</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug-AZD8931</intervention_name>
    <description>Active drug for biological activity</description>
    <arm_group_label>AZD8931</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug-Placebo</intervention_name>
    <description>Placebo comparator for biological activity comparison</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females aged 18 or older Early stage breast cancer and planned surgery

          -  Ineligible for Trastuzumab (Herceptin) treatment as per local guidelines

          -  World health Organisation performance status of 0 to 1 Tumour size amenable to
             obtaining adequate biopsies pre dosing.

        Exclusion Criteria:

          -  Eligible for Trastuzumab (Herceptin) Treatment Known sensitivity to AZD8931, its
             excipients or drugs in its class;

          -  Including oral tyrosine kinase inhibitors History of eye conditions e.g. previous
             injury within 3 months or clinically significant eye disease

          -  Concurrent malignancy Unable to discontinue medication or herbal supplement known to
             inhibit CYP3A4 or CYP2D6
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serban Ghiorghiu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Internal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wittenberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yonsei</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2012</study_first_posted>
  <last_update_submitted>December 13, 2012</last_update_submitted>
  <last_update_submitted_qc>December 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Neoplasm</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Breast Tumour</keyword>
  <keyword>Cancer of Breast</keyword>
  <keyword>Cancer of the Breast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

